
Podcast #160 · 9 Apr 2024
The Evolution of Bladder Cancer Treatment: New Insights on Lymphadenectomy
- Urologic Oncology
- Genomic Testing
- Clinical Trials
- Pelvic Lymph Node Dissection (PLND)
- Cystectomy
- Circulating Tumor DNA (ctDNA)
- Neoadjuvant Chemotherapy
- Bladder Cancer
This week on BackTable Urology, Dr. Seth Lerner (Baylor College of Medicine) discusses the intricacies of lymph node dissection in bladder cancer management, including an overview of patterns of metastasis, genomic classifiers, and recent clinical trials.
This podcast is supported by
Timestamps
More about this episode
The discussion highlights the evolution of bladder cancer treatment, from the use of cytotoxic chemotherapy to the current practice of neoadjuvant chemotherapy and radical cystectomy. Dr. Lerner and Dr. Bagrodia further explore diagnostic and treatment strategies, including the role of Decipher Prostate Genomic Classifier in tailoring patient treatment plans. The podcast delves into the necessity of a multidisciplinary approach to bladder cancer, the benefits of multimodal therapy, and the integration of circulating tumor DNA in management plans. Dr. Lerner then discusses clinical trials assessing the impact of extended lymph node dissection during cystectomies and emphasizes the importance of surgical quality and adherence to established protocols in bladder cancer treatment.

